PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary: The introduction of PD‐1/PD‐L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice‐changing activity in various types of solid tumours. Among haematological malignancies, PD‐1/PD‐L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over‐expression of PD‐1 ligands (PD‐L1, PD‐L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the US Food and Drug Administration approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication. Although the results in other lymphoid malignancies have not been so striking, blockade of the PD‐1/PD‐L1 axis has led to meaningful responses in other lymphoma types such as diffuse large B‐cell lymphoma, follicular lymphoma or several T‐cell lymphomas. Monotherapy with PD‐1/PD‐L1 inhibitors in chronic lymphocytic leukaemia and multiple myeloma has been unsatisfactory, suggesting that a combinational approach with other synergistic drugs is needed. In the case of multiple myeloma, immunomodulatory agents together with corticosteroids represent the most promising combinations. Among myeloid malignancies, the anti‐PD‐1 monoclonal antibodies are examined dominantly in acute myeloid leukaemia and myelodysplastic syndromes in combination with potentially synergistic hypomethylating drugs such as 5‐azacitidine, resulting in promising outcomes that warrant further investigation. We have described all available clinical results of PD‐1/PD‐L1 inhibitors in haematological malignancies and discussed related toxicities, as well as highlighted crucial preclinical studies in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Bailly, C., Thuru, X., & Quesnel, B. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa002 · Cited by 249
“(46) 5-AZA upregulates PD-1, PD-L1 and PD-L2 transcripts and protein in patients with AML/MDS; upregulation associated with drug resistance.”
BackgroundBone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
Noviello, M., Manfredi, F., Ruggiero, E., Perini, T., Oliveira, G., Cortesi, F., De Simone, P., Toffalori, C., Gambacorta, V., Greco, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08871-1 · Cited by 196
de Charette, M., & Houot, R. (2018) · Haematologica · doi:10.3324/haematol.2017.184192 · Cited by 129
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013
Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.15888 · Cited by 82
Tremblay-LeMay, R., Rastgoo, N., & Chang, H. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0589-1 · Cited by 69
Chen, D., Tang, P., Liu, L., Wang, F., Xing, H., Sun, L., & Jiang, Z. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442624 · Cited by 48
“The majority of studies imply that counts of PD-1 cells in MM microenvironment or peripheral blood increase and may be associated with worse prognosis [44,55].”
BackgroundLiu, Z., Mi, F., Han, M., Tian, M., Deng, L., Meng, N., Luo, J., & Fu, R. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13594 · Cited by 29
Metadata
- Authors
- Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., & Hajek, R.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2017-08-04
- Volume
- 152
- Issue
- 3
- Pages
- 357-371
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2732403960
- Cited by
- 122
- References
- 17
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.